DNAprint Genomics (DNAG)

[mingwan0]

From the press release:

Biofrontera AG today announced that it has acquired from ASAT AG, Zug, Switzerland all intellectual property, know-how and material related to a phase II compound for the treatment of various cancerous and precancerous skin lesions and some gynecological indications. The product applies aminolevulinic acid (ALA) in a patented nanocolloid formulation, ideally suited for photodynamic therapy (PDT).

Here is some more information on the compound itself:

http://content.karger.com/ProdukteDB/produkte.asp?Aktion=ShowFulltext&ProduktNr=224164&Ausga...

Photodynamic Therapy of Superficial Basal Cell Carcinomas Using Topical 5-Aminolevulinic Acid in a Nanocolloid Lotion
A.F. Hürlimanna, G. Hänggib, R.G. Panizzona

aDepartment of Dermatology, University Hospital Zurich,
bASAT AG Applied Science and Technology, Zug, Switzerland

Dermatology 1998;197:248-254

Results: After a single treatment, 47 (85%) basal cell carcinomas showed a complete response at a follow-up time of at least 6 months. For the remaining 8 (15%) lesions, a partial response was observed, indicated by a marked reduction of the tumor size. The treatment modality without local anesthetics was well tolerated by all patients, with only slight discomfort during light irradiation. Conclusion: Our results indicate that 5-ALA-PDT with our novel formulation, a nanocolloid lotion, is a highly effective and convenient therapy for the treatment of superficial basal cell carcionomas.

http://www.research-projects.unizh.ch/med/unit41300/area52/p1441.htm

Conclusions: Fluorescence hysteroscopy following intrauterine application of ALA may provide a more accurate, targeted and less invasive diagnostic procedure for cancerous lesions of the endometrium especially in patients desiring to preserve fertility and organ preserving treatment.